With Dutch biotech Crucell (CRCL.AS) about to be gobbled up by U.S. giant Johnson & Johnson (JNJ.N), its chief executive Ronald Brus will need to deliver new vaccines quickly to make a success of the acquisition. The deal looks in the bag after Crucell shareholders voted through changes to its statutes and approved the nomination of mostly J&J employees to its advisory board earlier on Tuesday. [ID:nLDE71707S] Brus is set to stay on at Crucell's vaccine business following the 1.75 billion euro ($2.4 billion) deal, but will face pressure to roll out products with enormous financial potential such as flu vaccines as soon as possible. His masterstroke at Crucell was to spot the gap in the market for vaccines against childhood diseases. He bought Swiss vaccine maker Berna Biotech in 2006. That gave Crucell the rights to Quinvaxem, which bundles vaccines against five common childhood diseases including diphtheria, tetanus, whooping cough, hepatitis B and influenza.
Source
